NBIX
HealthcareNeurocrine Biosciences, Inc.
$135.99
$-4.61 (-3.28%)
Jan 5, 2026
Price History (1Y)
Analysis
Neurocrine Biosciences, Inc. is a biopharmaceutical company headquartered in San Diego, California. The firm operates within the Healthcare sector and Drug Manufacturers - Specialty & Generic industry, boasting a significant scale with a market capitalization of $13.56B, annual revenues of $2.68B, and over 1,800 employees. The company's financial health is characterized by substantial profitability. Neurocrine Biosciences boasts a gross margin of 63.2%, an operating margin of 30.1%, and a profit margin of 16.0%. The firm also generates robust returns on equity (15.0%) and assets (8.7%). Its balance sheet shows a manageable debt-to-equity ratio of 15.97, with sufficient liquidity provided by $1.11B in cash reserves. Neurocrine Biosciences' valuation is marked by relatively high price multiples. The company's P/E ratio stands at 33.58 (TTM) and 14.82 (forward), while its EV/EBITDA multiple reaches 23.48. Revenue growth has been substantial, with a year-over-year increase of 27.8%, accompanied by an earnings growth rate of 64.5%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $13.56B
- P/E Ratio
- 33.58
- 52-Week High
- $160.18
- 52-Week Low
- $84.23
- Avg Volume
- 981.46K
- Beta
- 0.28
Company Info
- Exchange
- NMS
- Country
- United States
- Employees
- 1,800